BG
CLVS

BlackRock Group’s Clovis Oncology, Inc. CLVS Stock Holding History

BlackRock Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$930K Sell
20,918
-5,342
-20% -$188K ﹤0.01% 2162
2016
Q3 		$947K Buy
26,260
+8,335
+46% +$179K ﹤0.01% 2062
2016
Q2 		$246K Sell
17,925
-2,825
-14% -$41.3K ﹤0.01% 2505
2016
Q1 		$398K Buy
20,750
+3,895
+23% +$82.4K ﹤0.01% 2325
2015
Q4 		$589K Buy
16,855
+789
+5% +$50.9K ﹤0.01% 2128
2015
Q3 		$1.48M Buy
16,066
+4,887
+44% +$423K ﹤0.01% 1664
2015
Q2 		$982K Buy
11,179
+5,307
+90% +$454K ﹤0.01% 1970
2015
Q1 		$435K Buy
5,872
+1,063
+22% +$75.1K ﹤0.01% 2247
2014
Q4 		$269K Buy
4,809
+385
+9% +$20.2K ﹤0.01% 2430
2014
Q3 		$201K Sell
4,424
-110
-2% -$4.59K ﹤0.01% 2452
2014
Q2 		$188K Sell
4,534
-4,874
-52% -$251K ﹤0.01% 2473
2014
Q1 		$652K Buy
9,408
+2,216
+31% +$163K ﹤0.01% 2151
2013
Q4 		$433K Sell
7,192
-23,798
-77% -$1.29M ﹤0.01% 2256
2013
Q3 		$1.88M Sell
30,990
-29,589
-49% -$2.1M ﹤0.01% 1504
2013
Q2 		$4.06M Buy
+60,579
New +$2.72M ﹤0.01% 1033

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock Group's CLVS Position: Q4 2016 in Review

BlackRock Group reduced its Clovis Oncology, Inc. (CLVS) stake by 20% in Q4 2016, selling an estimated $188K and leaving 20,918 shares worth $930K. The position accounts for ﹤0.01% of the portfolio, ranked #2162.

BlackRock Group first reported a position in CLVS in Q2 2013 and has held it in 15 quarters since. The position peaked at $4.06M in Q2 2013. 167 funds tracked by Wall St. Rank hold CLVS as of Q4 2016.

  • BlackRock Group held 20,918 shares of Clovis Oncology, Inc. worth $930K as of Q4 2016.
  • BlackRock Group sold 5,342 Clovis Oncology, Inc. shares in Q4 2016, an estimated $188K.
  • Clovis Oncology, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2162 holding.
  • BlackRock Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Clovis Oncology, Inc. position peaked at $4.06M in Q2 2013.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.